Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
market size is estimated to grow by USD 4.37 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 28.21% during the forecast period. High unmet need for duchenne muscular dystrophy therapeutics is driving market growth, with a trend towards strong pipeline for duchenne muscular dystrophy therapeutics. However, high treatment costs of duchenne muscular dystrophy poses a challenge.Key market players include BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., and Wave Life Sciences Ltd.. AI-Powered Market Evolution Insights. Our comprehensive market report re
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- CAMP4 Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024PR Newswire
BMRN
Earnings
- 10/29/24 - Beat
BMRN
Sec Filings
- 11/14/24 - Form 4
- 11/12/24 - Form 144
- 10/31/24 - Form 10-Q
- BMRN's page on the SEC website